Randomized cross-over comparison of intravenous and subcutaneous darbepoetin dosing efficiency in haemodialysis patients

Nephrology

Volumn 10, Issue 2, 2005, Pages 129-135

  Cervelli, Matthew J ^a   Gray, Nicholas ^a   McDonald, Stephen ^a   Gentgall, Melanie G ^a   Disney, Alex P S ^a  

^a QUEEN ELIZABETH HOSPITAL   (Australia)

Author keywords

Darbepoetin; Dose; Efficiency; Intravenous; Subcutaneous

Indexed keywords

NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE RESPONSE; DRUG EFFICACY; FEMALE; FOLLOW UP; HEMODIALYSIS; HEMOGLOBIN DETERMINATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STATISTICAL ANALYSIS; TITRIMETRY;

ADULT; AGED; ANEMIA; CROSS-OVER STUDIES; ERYTHROPOIETIN; FEMALE; HEMOGLOBINS; HUMANS; INJECTIONS, INTRAVENOUS; INJECTIONS, SUBCUTANEOUS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PATIENT DROPOUTS; RENAL DIALYSIS;

EID: 20144376223     PISSN: 13205358     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-1797.2005.00386.x     Document Type: Article

References (25)

1. Bommer J, Ritz E, Weinreich T, Bommer G, Ziegler T. Subcutaneous erythropoietin. Lancet 1988; 13: 406.
2. McMahon LP, Dawborn JK. Experience with low dose intravenous and subcutaneous administration or recombinant human erythropoietin. Am. J. Nephrol. 1990; 10: 404-8.
3. Eschbach JW, Kelly MR, Haley RN, Abels RI, Adamson JW. Treatment of the anaemia of progressive renal failure with recombinant humanerythropoietin. N. Engl. J. Med. 1989; 321: 158-63.
4. Besarab A, Reyes CM, Hornberger J. Meta-analysis of subcutaneous versus intravenous epoetin in maintenance treatment of anaemia in hemodialysis patients. Am. J. Kidney Dis. 2002; 40: 439-46.
5. Lim VS, Degowin RL, Zavala D et al. Recombinant human erythropoietin treatment in pre-dialysis patients. Ann. Intern. Med. 1989; 110: 108-14.
6. Nissenson AR. Subcutaneous versus intravenous administration of epoetin in renal patients. New Dimensions Treat. Anaemia 2000; 10: 31-7.
7. Boelaert J, Schurgers M, Matthys E. Comparative pharmacokinetics of recombinant erythropoietin administered by the intravenous, subcutaneous and intraperitoneal routes in continous ambulatory peritoneal dialysis patients (CAPD). Perit. Dial. Int. 1989; 9: 95-8.
8. Salmonson T, Danielson BG, Grahnen A, Wikstrom B. Pharmacokinetics of intravenous recombinant human erythropoietin in patients with chronic renal failure. J. Intern. Med. 1990; 228: 53-7.
9. Halstenson CE, Macres M, Katz SA. Comparative pharmacokinetics and pharmacodynamics of epoetin alfa and epoetin beta. Clin. Pharmacol. Ther. 1991; 50: 702-12.
10. Salmonson T. Pharmacokinetic and pharmacodynamic studies of recombinant human erythropoetin. Scand. J. Urol. Nephrol. Suppl. 1990; 129: S1-S66.
11. Macdougall IC, Roberts DE, Neubert P et al. Pharmacokinetics of recombinant human erythropoietin in patients on continuous ambulatory peritoneal dialysis. Lancer 1989; 1: 425-7.
12. Egrie JC, Eschbach JW, McGuire T, Adamson JW. Pharmacokinetics of recombinant human erythropoietin (Rhuepo) administered to hemodialysis (Hd) patients. Kidney Int. 1988; 33: 262.
13. Macdougall IC, Roberts DE, Coles GA, Williams JD. Clinical pharmacokinetics of epoetin (recombinant human erythropoietin). Clin. Pharmacokinet. 1991; 20: 99-113.
14. Besarab A, Flaharty KK, Erslev AJ et al. Clinical pharmacology and economics of recombinant human erythropoietin in end-stage renal disease: The case for subcutaneous administration. J. Am. Soc. Nephrol. 1992; 2: 1405-16.
15. Lappin TRJ, Rich IN. Erythropoietin: The first 90 years. Clin. Lab. Haematol. 1996; 94: 1-6.
16. Rice L, Alfrey CP, Driscoll T et al. Neocytolysis contributes to the anaemia of renal disease. Am. J. Kidney Dis. 1999; 33: 59-62.
17. Casadevall N, Nataf J, Viron B et al. Pure red-cell aplasia and anti-erythropoietin antibodies in patients treated with recombinant erythropoietin. N. Engl. J. Med. 2002; 346: 469-70.
18. Egrie JC, Browne JK. Development and characterization of novel erythropoiesis stimulating protein (Nesp). Nephrol. Dial. Transplant. 2001; 16: 3-13.
19. Vanrenterghem Y, Barany P, Mann JF et al. Randomized trial of darbepoetin alfa for treatment of renal anemia at a reduced dose frequency compared with R-huepo in dialysis patients. Kidney Int. 2002; 62: 2167-75.
20. Locatelli F, Canaud B, Giacardy F et al. Treatment of anaemia in dialysis patients with unit dosing of darbepoetin alfa at a reduced dose frequency relative to recombinant human erythropoietin (Rhuepo). Nephrol. Dial. Transplant. 2003; 18: 362-9.
21. Macdougall IC, Gray SJ, Elston O et al. Pharmacokinetics of novel erythropoiesis stimulating protein compared with epoetin alfa in dialysis patients. J. Am. Soc. Nephrol 1999; 10: 2392-5.
22. Canaud B. Darbepoetin alfa dose requirements for iv and sc administration are equivalent in anaemic dialysis patients. Nephrol. Dial. Transplant. 2002; 17: 137.
23. Graf H, Lacombe J-L, Braun J, Gomes da Costa AA. Novel erythropoiesis stimulating protein (Nesp) effectively maintains hemoglobin (Hb) when administered at a reduced dose frequency compared with recombinant human erythropoietin (R-huepo) in esrd patients. J. Am. Soc. Nephrol. 2000; 11: 1317A.
24. Amgen Anaemia Advisory Group. Darbepoetin alfa: a new erythropoietic drug for the treatment of renal anaemia. Nephrology 2002; 7: S173-80.
25. Paganini EP, Eschbach JW, Lazarus M et al. Intravenous versus subcutaneous dosing of epoetin alfa in hemodialysis patients. Am. J. Kidney Dis. 1995; 26: 331-40.